Wentao Fu

2.1k total citations · 1 hit paper
25 papers, 1.4k citations indexed

About

Wentao Fu is a scholar working on Oncology, Molecular Biology and Infectious Diseases. According to data from OpenAlex, Wentao Fu has authored 25 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Molecular Biology and 4 papers in Infectious Diseases. Recurrent topics in Wentao Fu's work include Metal complexes synthesis and properties (5 papers), SARS-CoV-2 and COVID-19 Research (3 papers) and Machine Learning in Materials Science (3 papers). Wentao Fu is often cited by papers focused on Metal complexes synthesis and properties (5 papers), SARS-CoV-2 and COVID-19 Research (3 papers) and Machine Learning in Materials Science (3 papers). Wentao Fu collaborates with scholars based in United States, United Kingdom and China. Wentao Fu's co-authors include Michael E. Johnson, Andrew D. Mesecar, Arun K. Ghosh, Kiira Ratia, Susan C. Baker, Richard Pazdur, Thomas R. Cundari, Kirsten B. Goldberg, Rima Chaudhuri and Jun Takayama and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Biochemistry and The Journal of Physical Chemistry.

In The Last Decade

Wentao Fu

25 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia

2018 252 citations Aviva C. Krauss, Xin Gao et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Wentao Fu

Since Specialization

Citations

This map shows the geographic impact of Wentao Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wentao Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wentao Fu more than expected).

Fields of papers citing papers by Wentao Fu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wentao Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wentao Fu. The network helps show where Wentao Fu may publish in the future.

Co-authorship network of co-authors of Wentao Fu

This figure shows the co-authorship network connecting the top 25 collaborators of Wentao Fu. A scholar is included among the top collaborators of Wentao Fu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wentao Fu. Wentao Fu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma 2024 ·Clinical Cancer Research ·Michael H. Brave, William F. Maguire, Chana Weinstock, (unknown), Xin Gao, (unknown), Jingyu Yu, Wentao Fu, (unknown), William F. Pierce, Elaine Chang, Jeannette Dinin, Mallorie H. Fiero, Nam Atiqur Rahman, Shenghui Tang, Richard Pazdur, Paul G. Kluetz, Laleh Amiri‐Kordestani, Daniel L. Suzman	14
2	FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2 -Positive RAS Wild-Type Colorectal Cancer 2023 ·Clinical Cancer Research ·Sandra J. Casak, M. Naomi Horiba, Mengdie Yuan, Joyce Cheng, Steven J. Lemery, Yuan Li Shen, Wentao Fu, (unknown), (unknown), Youwei Bi, (unknown), (unknown), Paul G. Kluetz, Richard Pazdur, Lola A. Fashoyin‐Aje	21
3	FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation 2021 ·Clinical Cancer Research ·Dianne Pulte, Kelly J. Norsworthy, Yaping Wang, (unknown), Hisham Qosa, Ramadevi Gudi, Donna Przepiorka, Wentao Fu, Ólanrewaju O. Okusanya, Kirsten B. Goldberg, R. Angelo de Claro, Ann T. Farrell, Richard Pazdur	57
4	FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia breakdown → 2018 ·Clinical Cancer Research ·Aviva C. Krauss, Xin Gao, Liang Li, Michael L. Manning, Paresma Patel, Wentao Fu, Kumar G. Janoria, Gerlie Gieser, David A. Bateman, Donna Przepiorka, Yuan Li Shen, Stacy S. Shord, Christopher M. Sheth, Anamitro Banerjee, Jiang Liu, Kirsten B. Goldberg, Ann T. Farrell, Gideon M. Blumenthal, Richard Pazdur	252
5	FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer 2018 ·Clinical Cancer Research ·Anand Shah, Erik Bloomquist, Shenghui Tang, Wentao Fu, Youwei Bi, Qi Liu, Jingyu Yu, Ping Zhao, Todd R. Palmby, Kirsten B. Goldberg, (unknown), Paresma Patel, (unknown), Amy Tilley, William F. Pierce, Amna Ibrahim, Gideon M. Blumenthal, Rajeshwari Sridhara, Julia A. Beaver, Richard Pazdur	88
6	FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy 2017 ·The Oncologist ·Yang‐Min Ning, Daniel L. Suzman, V. Ellen Maher, Lijun Zhang, Shenghui Tang, Tiffany K. Ricks, Todd R. Palmby, Wentao Fu, Qi Liu, Kirsten B. Goldberg, Geoffrey Kim, Richard Pazdur	112
7	FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer 2016 ·Clinical Cancer Research ·Amanda J. Walker, Suparna Wedam, Laleh Amiri‐Kordestani, Erik Bloomquist, (unknown), Rajeshwari Sridhara, Wei Chen, Todd R. Palmby, Jeanne Fourie Zirkelbach, Wentao Fu, Qi Liu, Amy Tilley, Geoffrey Kim, Paul G. Kluetz, Amy E. McKee, Richard Pazdur	104
8	Synthesis, characterization, cytotoxicity of mixed ligand complexes of palladium(II) with dipyrido[3,2-d:2′,3′-f]quinoxaline/dipyrido[3,2-a:2′,3′-c](6,7,8,9-tetrahydro)phenazine and 4-toluensulfonyl-L-amino acid dianion 2014 ·European Journal of Medicinal Chemistry ·Lili Ma, Kun Ge, Ran Zhang, Wentao Fu, Shenghui Li, Shuxiang Wang, Guoqiang Zhou, Xinying Qin, Jinchao Zhang	9
9	Metabolism and disposition of ABT-894, a novelα4β2 neuronal acetylcholine receptor agonist, in mice and monkeys 2014 ·Xenobiotica ·Hong Liu, Wentao Fu, Jill M. Wetter, Hongyu Xu, Zhiwen Guan, (unknown)	2
10	Glutamate Racemase Dimerization Inhibits Dynamic Conformational Flexibility and Reduces Catalytic Rates 2009 ·Biochemistry ·Shahila Mehboob, Liang Guo, Wentao Fu, Anuradha Mittal, (unknown), Kent Truong, (unknown), Fei Long, Leslie W.‐M. Fung, Michael E. Johnson	15
11	A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication 2008 ·Proceedings of the National Academy of Sciences ·Kiira Ratia, Scott D. Pegan, Jun Takayama, Katrina Sleeman, Melissa M. Coughlin, Surendranath Baliji, Rima Chaudhuri, Wentao Fu, Bellur S. Prabhakar, Michael E. Johnson, Susan C. Baker, Arun K. Ghosh, Andrew D. Mesecar	366
12	Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors 2007 ·Bioorganic & Medicinal Chemistry Letters ·Arun K. Ghosh, Kai Xi, Valerie Grum‐Tokars, Xiaoming Xu, Kiira Ratia, Wentao Fu, Katherine V. Houser, Susan C. Baker, Michael E. Johnson, Andrew D. Mesecar	82
13	Design, synthesis, and evaluation of oxyanion-hole selective inhibitor substituents for the S1 subsite of factor Xa 2004 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Oukseub Lee, Quan Z. Sheng, Wentao Fu, Debbie C. Mulhearn, David Crich, Andrew D. Mesecar, Michael E. Johnson	4
14	An oxyanion-Hole selective serine protease inhibitor in complex with trypsin 2002 ·Bioorganic & Medicinal Chemistry ·Jiandong Cui, (unknown), Wentao Fu, David Crich, Andrew D. Mesecar, Michael E. Johnson	11
15	Interference Estimation and Mitigation for STAP Using the Two-Dimensional Wold Decomposition Parametric Model 2000 ·Defense Technical Information Center (DTIC) ·Joseph M. Francos, Wentao Fu, Arye Nehorai	1
16	Genetic algorithm optimization of a molecular mechanics force field for technetium 2000 ·Inorganica Chimica Acta ·Thomas R. Cundari, Wentao Fu	20
17	PM3(tm) parameterization using genetic algorithms 2000 ·International Journal of Quantum Chemistry ·Thomas R. Cundari, Jun Deng, Wentao Fu	33
18	Molecular Modeling of Catalysts and Catalytic Reactions 1998 ·Journal of Chemical Information and Computer Sciences ·Thomas R. Cundari, Jun Deng, Wentao Fu, (unknown), Akihiko Yoshikawa	5
19	Conformational analysis of platinum antitumor drugs 1998 ·Journal of Molecular Structure THEOCHEM ·Thomas R. Cundari, Wentao Fu	7
20	Molecular Mechanics Force Field for Platinum Coordination Complexes 1996 ·The Journal of Physical Chemistry ·Thomas R. Cundari, Wentao Fu, (unknown), (unknown), (unknown), Shaun O. Sommerer, (unknown)	39

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact